Literature DB >> 3005412

Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.

A Harel-Bellan, J Bertoglio, A Quillet, C Marchiol, H Wakasugi, Z Mishall, D Fradelizi.   

Abstract

Several reports indicate that human peripheral blood lymphocytes (PBL) seeded in culture with purified or recombinant interleukin 2 (IL 2) immediately after separation from the blood display a substantial level of proliferation at day 5 or 6, even in the absence of any activating signal. The spontaneously IL 2 proliferating cells are large lymphocytes, and they co-purify on a Percoll gradient in the large granular lymphocytes (third (LGL) fraction) together with the natural killer (NK) activity. When LGL were separated into NKH1 (an NK-specific surface marker)-positive and NKH1-negative cells by fluorescence-activated cell sorting (FACS), proliferating cells were mainly found in the NKH1-negative fraction. On the contrary, when cells from Percoll fraction 3 were separated into OKT3-negative and positive cells, the majority of the proliferating cell was found in the OKT3-positive cells. These results indicate that spontaneously IL 2 proliferating (SIP) cells most probably belong to the T cell lineage, but are distinct from NK cells. Surprisingly, cells from this Percoll fraction examined immediately after separation from the blood do not express detectable amounts of IL 2 receptors as assessed by three different techniques: binding of [3H]IL 2, binding of [125I]anti-Tac antibodies, and FACS analysis with the use of anti-Tac antibodies. However, after 18 hr of culture in IL 2-supplemented medium, 5 to 7% of these cells became Tac-positive by FACS analysis. Additional analysis of IL 2 receptor induced in culture with IL 2 was performed by [125I]anti-TAC binding and by [3H]IL 2 binding. Scatchard analysis of [3H]IL 2 binding, in the range of concentrations leading to the detection of high-affinity binding sites, showed an affinity constant similar to that of conventional phytohemagglutinin blasts. The role of IL 2/IL 2 receptor interaction in the proliferation process was confirmed by the fact that proliferation, in contrast with NK activation, was clearly inhibited by anti-Tac antibodies. When LGL activated with IL 2 for 60 hr were sorted into Tac+ and Tac- cells, equal levels of NK activity was found in the two fractions. Proliferation, however, was only observed in the Tac+ population. We interpret these results to indicate that SIP cells are preactivated cells circulating in the blood. They are large cells and represent a very small proportion of circulating lymphocytes (0.3%). They express a subliminal amount of IL 2 receptor. Cultivated in the presence of IL 2, IL 2 receptor expression is enhanced to a detectable level, and the SIP cells begin to proliferate. These SIP cells could be activated T cells present in every normal individual.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005412

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Flow cytometry resonance energy transfer suggests an association between low-affinity interleukin 2 binding sites and HLA class I molecules.

Authors:  A Harel-Bellan; P Krief; L Rimsky; W L Farrar; Z Mishal
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

2.  Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.

Authors:  B M Foxwell; J Simon; J J Herrero; D Taylor; G Woerly; D Cantrell; B Ryffel
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

3.  IL-2-induced polyclonal proliferation of human peripheral blood lymphocytes: functional and phenotypic characteristics of proliferating cells.

Authors:  B K Mookerjee; P B Chen; J L Pauly
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

4.  Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes.

Authors:  N E Kay; J E Morley; J I Allen
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

5.  Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal.

Authors:  J Woo; C S Ross; J I Milton; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

6.  Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7.

Authors:  C A Maxwell-Armstrong; L G Durrant; R A Robins; A M Galvin; J H Scholefield; J D Hardcastle
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

7.  Activation and proliferation of normal resting human T lymphocytes in serum-free culture: role of IL-4 and IL-6.

Authors:  D Habetswallner; E Pelosi; D Bulgarini; A Camagna; P Samoggia; E Montesoro; G Giannella; D Lazzaro; G Isacchi; U Testa
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

8.  Mechanisms underlying T-lymphocyte activation: mitogen initiates and IL-2 amplifies the expression of transferrin receptors via intracellular iron level.

Authors:  E Pelosi-Testa; P Samoggia; G Giannella; E Montesoro; T Caravita; G Salvo; A Camagna; G Isacchi; U Testa; C Peschle
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

9.  Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Ti gamma/delta or TNK phenotype.

Authors:  U Testa; A Care; E Montesoro; C Fossati; G Giannella; R Masciulli; M Fagioli; D Bulgarini; D Habetswallner; G Isacchi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 10.  Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.

Authors:  Charles Maxwell-Armstrong
Journal:  Ann R Coll Surg Engl       Date:  2002-09       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.